Although their activity is not restricted to NF-κB, proteasome inhibitors leverage the unfolded protein response co-opted by the tumour cells to cope with the increased build-up of proteins, and were postulated to impair the degradation of the canonical NF-κB inhibitor IκBα, thereby preventing activation of this pathway [136]. This evidence concerns the gene NFKB1 and neoplasm.